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Reduced brain-derived neurotrophic factor (BDNF) signaling has been shown in the
frontal cortex and hippocampus in schizophrenia. The aim of the present study was to
investigate whether a BDNF deficit would modulate effects of chronic cannabis intake,
a well-described risk factor for schizophrenia development. BDNF heterozygous mice
(HET) and wild-type controls were chronically treated during weeks 6, 7, and 8 of life
with the cannabinoid receptor agonist, CP55,940 (CP). After a 2-week delay, there were
no CP-induced deficits in any of the groups in short-term spatial memory in a Y-maze
task or novel object recognition memory. Baseline prepulse inhibition (PPI) was lower
but average startle was increased in BDNF HET compared to wild-type controls. Acute
CP administration before the PPI session caused a marked increase in PPI in male
HET mice pre-treated with CP but not in any of the other male groups. In females,
there were small increases of PPI in all groups upon acute CP administration. Acute
CP administration furthermore reduced startle and this effect was greater in HET mice
irrespective of chronic CP pre-treatment. Analysis of the levels of [3H]CP55,940 binding by
autoradiography revealed a significant increase in the nucleus accumbens of male BDNF
HET mice previously treated with CP but not in any of the other groups or in the caudate
nucleus. These results show that BDNF deficiency and chronic young-adult cannabinoid
receptor stimulation do not interact in this model on learning and memory later in life.
In contrast, male “two hit” mice, but not females, were hypersensitive to the effect of
acute CP on sensorimotor gating. These effects may be related to a selective increase of
[3H]CP55,940 binding in the nucleus accumbens, reflecting up-regulation of CB1 receptor
density in this region. These data could be of relevance to our understanding of differential
“two hit” neurodevelopmental mechanisms in schizophrenia.
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INTRODUCTION
It is becoming widely accepted that the development of
schizophrenia cannot be explained by single gene mutations or
environmental factors. Instead, multiple factors, e.g., gene poly-
morphisms which increase risk, and environmental insults, such
as stress or drug abuse, are likely to act synergistically to trigger
disease onset, a model commonly referred to as the “two hit”
hypothesis of schizophrenia (Bayer et al., 1999; Maynard et al.,
2001; McGrath et al., 2003). Several animal model studies are
attempting to delineate the molecular mechanisms involved in
this synergism, with the ultimate aim to provide new treatment
targets, including for early intervention. For example, studies
have shown that temporary treatment with low doses of antipsy-
chotics in late adolescence may be effective in preventing the
emergence of schizophrenia-like behavioral phenotype in neu-
rodevelopmental animal models of the illness (Piontkewitz et al.,
2009). However, the mechanisms involved in such preventative
treatments remain unclear.
Brain-derived neurotrophic factor (BDNF) is involved in brain
development and neuroplasticity (Monteggia et al., 2004; Lu et al.,
2008). Altered BDNF signaling has been implicated in a number
of psychiatric illnesses, including schizophrenia and depression
(Angelucci et al., 2005; Autry and Monteggia, 2012). For exam-
ple, post-mortem studies have found significant reductions of
BDNF gene expression and protein levels in the brains of peo-
ple with schizophrenia (Hashimoto et al., 2003; Weickert et al.,
2003; Durany and Thome, 2004). Levels of BDNF in the brain are
modulated by stress in an age-, sex-, and stress-type-dependent
manner (Bath et al., 2013). We have previously used chronic
administration of the stress hormone, corticosterone, as a model
of late adolescent/early adulthood stress. Corticosterone treat-
ment in BDNF heterozygous (HET) mice caused sex-specific
long-term effects in the Y-maze and other effects (Klug et al.,
2012).
Cannabis abuse may precipitate psychosis development in vul-
nerable individuals, much like a “two hit” effect (Van Os et al.,
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2002; Henquet et al., 2008; Gururajan et al., 2012). BDNF may
be part of the neurochemical mechanism involved in this interac-
tion. Previous studies have shown that cannabis use can alter lev-
els of BDNF in humans as well as in animals (Derkinderen et al.,
2003; Jockers-Scherübl et al., 2004; Butovsky et al., 2005; D’souza
et al., 2009). For example, injection of 9-tetrahydrocannabinol
(THC) has been shown to upregulate BDNF expression in rats
and mice (Derkinderen et al., 2003; Butovsky et al., 2005) and
BDNF serum levels in healthy humans (D’souza et al., 2009).
However, in human studies looking at chronic abuse of cannabis,
it is not as clear in which direction cannabis exerts its influence
on BDNF. While some have shown that chronic cannabis users
have lower basal levels of serum BDNF (D’souza et al., 2009)
others could not detect such differences (Jockers-Scherübl et al.,
2004; Angelucci et al., 2008). In a study focusing on the val66met
BDNF polymorphism, in female psychotic patients, cannabis use
was associated with a 7 year-earlier onset of the disease when
patients were BDNF-Met carriers but not when they were Val/Val
genotypes (Decoster et al., 2011). These results suggest interac-
tions between cannabis use, BDNF and psychotic disorders, even
though the mechanism involved remains unclear. We recently
investigated maternal separation in rats as a first developmen-
tal “hit” and treated the animals with the cannabinoid receptor
agonist, CP55,940 (CP) (Klug and Van Den Buuse, 2012). Male
“two hit” rats, but not female rats, showed anhedonia-like behav-
ior and increased anxiety, but no deficits in short-term spatial
memory (Klug and Van Den Buuse, 2012). Thus, treatment with
CP in maternally-separated rats caused markedly different long-
term effects than those seen in BDNF HET mice treated with
corticosterone. This suggested marked qualitative differences in
the two hit effects of either stress (in the form of corticos-
terone treatment) compared to cannabis abuse (in the form
of chronic CP injections). However, species differences could
not be ruled out. Therefore, the present study is focused on
combining genetically-induced deficiency of BDNF in mice and
treatment with the cannabinoid receptor agonist, CP, during
adolescence/young adulthood.
We used BDNF heterozygous (HET) mice and treated them
with CP from 6 to 9 weeks of age (adolescence/young adulthood)
which represents a critical time window for detrimental effects
of cannabis abuse (Schneider, 2008). We investigated locomo-
tor activity at the beginning and end of treatment, as well as 2
weeks after treatment had ceased. To investigate whether cogni-
tion was affected in the animals, we used the Y-maze and the novel
object recognition test. Baseline PPI was compared between the
groups and, in addition, in a separate session the mice received
an acute injection of CP to see whether differences in reaction to
the drug would occur between animals previously treated with the
cannabinoid agonist and animals previously treated with vehicle.
METHODS
ANIMALS AND PROTOCOLS
Male and female BDNF heterozygous and wild-type control mice
were obtained from a breeding colony at the Florey Neuroscience
Institutes animal facility and brought over to the Mental Health
Research Institute at 4–5 weeks of age, where they were housed
in individually-ventilated cages (IVC). All experiments and
procedures were approved by the Animal Experimentation Ethics
Committee of the Florey Neuroscience Institutes, University of
Melbourne, Australia.
The mice received injections with 0.4mg/kg CP55,940 or
vehicle from 6 to 9 weeks of age. CP55,940 ((-)-cis-3-[2-hydroxy-
4-(1,1,-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)
cyclohexanol) was obtained from Tocris Bioscience (Bristol,
UK) and first dissolved in 100% ethanol and then diluted in
Tween 80 and saline to make a final vehicle solution of 2.5%
ethanol, 2.5% Tween 80, and 95% saline. Mice were injected
intraperitoneally (i.p.) once a day (at 9:00 am) on weekdays at a
dose of 0.4mg/kg in a volume of 10ml/kg. The treatment started
at 6 weeks of age and continued for 3 weeks until the mice were
9 weeks of age. The mice received no injections on the weekends.
Control animals received vehicle solution injections. Thus, there
were four male and four female experimental groups: wild-type
mice treated with vehicle (WT/veh), wild-type mice treated
with CP55,940 (WT/CP), BDNF heterozygous mice treated with
vehicle (HET/veh) and BDNF HET mice treated with CP55,940
(HET/CP). Each group consisted of 10–16 animals.
Body weights were obtained at 6 weeks of age (CP treatment
start), 9 weeks of age (end of CP treatment) and 12 weeks of age
(during behavioral testing). Behavioral testing started at 11 weeks
of age and included locomotor activity, Y-maze, novel object
recognition, and prepulse inhibition (PPI).
LOCOMOTOR ACTIVITY
To assess locomotor hyperactivity, mice were placed into individ-
ual automated photobeam activity cages (Tru Scan, Coulbourn
Instruments, Whitehall, PA, USA; 27 cm l × 27 cm w × 40 cm
h). Each cage was fitted out with photobeams which detected an
animal’s position at any one time during a session. The asso-
ciated software used this information to calculate the distance
moved in centimetres by the animal in 5min intervals. Mice were
placed into the chambers for 60min to habituate them to the new
environment and record baseline activity. Each animal was tested
three times for changes in locomotor activity: at the beginning
of CP treatment (6 weeks of age), at the end of the treatment (9
weeks of age) and 2 weeks after treatment had ceased (11 weeks
of age). During the first two sessions, the mice were placed into
the chambers immediately after injection with the daily dose of
CP or vehicle and total distance moved was recorded for 12 five
min blocks. At 11 weeks of age, locomotor activity was similarly
measured but the animals received no injection.
Y-MAZE
Short-term spatial memory was assessed using the Y-maze (Dellu
et al., 1992, 2000), which consisted of three arms (30 cm l ×
8 cm w × 16 cm h) with geometric shapes on the wall and a
triangular central platform. In the first exposure session, animals
were placed facing the wall at the end of one arm (start arm)
and allowed to explore the Y-maze for 10min with one of the
two other arms closed-off (novel arm). After a retention period,
animals were placed back into the start arm and allowed to
explore all three arms of the maze for 5min. Behavior was
recorded on video and analyzed with video tracking software
(Ethovision, Noldus, The Netherlands). Behaviors analyzed were
time spent in each arm, percentage number of entries to each
arm and the overall number of arm entries to measure locomotor
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activity. We chose to display percentage number of entries to
account for possible differences in locomotor activity. Mice were
tested twice in the Y-maze with two different retention periods of
1 or 2 h (Dellu et al., 1992, 2000; Conrad et al., 2003) but because
similar results were obtained, only data pertaining to the 2-h
interval will be shown here.
NOVEL OBJECT RECOGNITION
Object recognition was assessed using the novel object recogni-
tion task. Two days before testing, animals were habituated to
the empty testing apparatus (40 cm l × 30 cm w × 10 cm h) for
10min each day. On the third day the animals were tested for
novel object recognition memory. On the testing day, two iden-
tical objects were placed in the right and left corner at the end
of the arena. The animals were then placed into the arena fac-
ing the opposite wall and were allowed to explore the objects for
10min (introduction phase). The animals were then removed and
returned back to their home cages for 2 h. Following the delay,
the animals were placed back into the arena, which now con-
tained one familiar object (from the introduction phase) and one
novel object. The animals were allowed to explore the objects for
5min (recognition phase). Behavior in both phases was recorded
on video and analyzed with video tracking software (TopScan,
CleverSys Inc., Reston, VA, USA). The time spent sniffing the
objects in the introduction phase was analyzed and used as a mea-
sure to detect side preference and interaction time. The time spent
sniffing the objects in the recognition phase was used as a mea-
sure of recognition. Animals that spent less than 10 s exploring
both objects were excluded from the analysis. The amount of time
spent investigating the novel object was expressed as percentage of
total object exploration time.
PREPULSE INHIBITION OF ACOUSTIC STARTLE
PPI was measured using eight automated startle chambers (SR-
LAB, San Diego Instruments, San Diego, CA, USA). Animals
were placed individually in a Plexiglas cylinder of 3.8 cm diameter
which was secured to a platform with a piezoelectric accelerom-
eter mounted under it to detect whole body startle responses.
The cylinders were placed in a ventilated, sound-attenuated and
well-lit startle box. Background noise and acoustic pulses were
presented through a speaker in the startle box and responses
weremeasured with the SR-Lab software (SanDiego instruments)
running on a computer in an adjacent room.
A single PPI session included 104 trials and lasted ∼40min.
There was an initial 3min acclimation period with continu-
ous background white noise only, set at 70 dB, which continued
throughout the rest of the entire session. The first and last eight
trials were presented at 115 dB. The 88 trials in-between were pre-
sented in a pseudo-random order and included sixteen 115 dB
startle pulses and 72 prepulse-pulse trials including eight of each
prepulse (PP) intensity of 2, 4, 8, 16 dB over baseline and eight
“no-stimulus” trials, where no pulse was presented. Each startle
pulse was 40ms in duration, the prepulse was 20ms and there
were either a 30 or 100ms inter-stimulus interval (ISI) between
the prepulse and the pulse. Because the clearest group differences
were observed with the 100ms ISI, only those data will be shown
here. Startle amplitude was analyzed as the average of all 115 dB
pulse-alone trials. Startle habituation was analyzed by using the
pulse-alone data in four blocks of eight trials. PPI was calculated
as the percentage difference of the responses to pulse-alone trials
minus prepulse trials divided by the response to pulse-alone trials.
The PPI experiment included a saline treatment session and
a challenge session with an acute injection of CP (0.4mg/kg).
Saline and CP were administered in a volume of 10ml/kg, 5min
prior to the PPI session. There were 3 days of drug wash-out in-
between the two test sessions. The order of drug administration
was randomized to control for the possibility of test habituation.
One week after the last behavioral test, mice were killed by cer-
vical dislocation and the brains stored at−80◦C until further use.
[3H]CP55,940 BINDING
The procedure was essentially as previously described (Chavez
et al., 2010) with modifications. Briefly, 20µm brain sections
including the cingulate cortex, caudate nucleus, and nucleus
accumbens were cut on a cryostat and thaw-mounted on gela-
tinized slides. On the day of the experiments, the slides were first
washed for 30min in a 50mM Tris HCl buffer with 1% BSA
(pH 7.4) at room temperature. The sections were then exposed
to either the total binding solution, containing [3H]CP55,940 at a
final concentration of 2 nM, or the non-specific binding solution
containing [3H]CP55,940 and 10µMof CP55,940 for 2 h at room
temperature. The reaction was terminated by three 20min washes
in ice cold buffer. The sections were then air-dried and partially
fixed in paraformaldehyde vapor overnight before being placed
in Fujifilm BAS 2025 cassettes (Berthold, Australia) and apposed
to BAS-TR2025 phosphoimaging plates (Berthold) for 6 days.
Autoradiographic images were analyzed using AIS image analy-
sis software (Imaging Research, ON, Canada). Binding densities
in the nucleus accumbens and caudate nucleus were quantitated
by comparing them to [3H]microscales and expressed as fmol/mg
estimated tissue equivalent (ETE) (Pavey et al., 2002; Chavez et al.,
2010). It should be noted that this single-point agonist bind-
ing method most likely represents high-affinity binding and does
not distinguish between possible changes in Kd or Bmax of the
receptor.
DATA ANALYSIS
Data were expressed as the mean ± the standard error of the
mean (SEM). Data analysis was conducted with the software pro-
gram SPSS Statistics GradPack 17.0 (SPSS Inc, Chicago, IL, USA).
All data were analyzed using a Three-Way analysis of variance
(ANOVA) with repeated measures where appropriate, with fac-
tors being sex, first “hit” (BDNF heterozygosity) and second “hit”
(CP) as main factors. When interactions were found, separate
Two-Way ANOVAs split by one of the independent factors or
pairwise comparisons of appropriate group combinations were
done to clarify the results (Nieuwenhuis et al., 2011). If P < 0.05,
differences were considered statistically significant.
RESULTS
BODY WEIGHT
At 6 weeks of age (start of drug treatment) female mice weighed
significantly less than male mice [main effect of sex: F(1, 98) =
135.2; P < 0.001] and HET mice had higher bodyweight com-
pared to their wild-type littermates [main effect of genotype:
F(1, 98) = 11.7; P = 0.001]. At 9 weeks of age (end of drug
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treatment) statistical analysis revealed a number of main effects
[main effect of sex: F(1, 98) = 290.7; P < 0.001; main effect of
genotype: F(1, 98) = 38.9; P < 0.001 and main effect of CP treat-
ment: F(1, 98) = 13.2; P < 0.001] and also a significant interac-
tion for sex × genotype [F(1, 98) = 4.8; P = 0.041]. Two-Way
ANOVAs split by sex revealed that male HET mice weighed
more compared to male wild-type mice [main effect of geno-
type: F(1, 49) = 8.2; P = 0.006] and CP-treated animals had lower
bodyweight compared to vehicle-treated mice independent of
genotype [main effect of CP treatment: F(1, 49) = 10.7; P =
0.002]. For female mice there was a significant main effect of
genotype with HET mice having higher bodyweights [F(1, 48) =
36.7; P < 0.001]. At 12 weeks of age (during behavioral test-
ing) the treatment effect of CP had disappeared but a significant
genotype effect remained for both males [F(1, 49) = 11.3; P =
0.002] and females [F(1, 48) = 42.2; P < 0.001] and with HET
mice weighing more than wild-types (Table 1).
LOCOMOTOR ACTIVITY
At the beginning of the CP treatment period at 6 weeks of age,
both sexes showed significantly reduced distance moved after the
injection compared to vehicle-injected controls [main effect of
CP: F(1, 46) = 109.4 for male mice and F(1, 43) = 207.0 for female
mice, both P < 0.001]. Additionally, in both sexes a significant
interaction for genotype × CP emerged [males: F(1, 46) = 4.4;
P = 0.042; females: F(1, 43) = 7.8; P = 0.008]. For male mice,
pairwise comparisons revealed that HETs were less active com-
pared to wild-type mice when treated with vehicle [F(1, 23) =
4.8; P = 0.040] but there were no differences after CP treatment
(Figure 1). For female mice, pairwise comparisons revealed that
HETs weremore active compared to wild-type controls [F(1, 24) =
5.4; P = 0.029]. However, when the mice had received CP injec-
tion, this phenotype was reversed with HETmice being less active
compared to wild-types [F(1, 18) = 9.5; P = 0.007].
At the end of CP treatment at 9 weeks of age, both male
and female mice still showed acute hypo-activity after CP injec-
tion compared to saline-injected controls [main effect of CP:
Table 1 | Bodyweight (grams) of wild-type (WT) and BDNF
heterozygous (HET) mice treated with vehicle (veh) or CP55,940 (CP)
at 6 weeks (beginning of drug treatment), 9 weeks (end of drug
treatment), and 12 weeks of age (during behavioral testing).
WT/veh WT/CP HET/veh HET/CP
MALE MICE
Week 6 21.4 ± 0.4 20.7 ± 0.5 21.9 ± 0.3 21.9 ± 0.5
Week 9 24.3 ± 0.5 22.7 ± 0.3 25.3 ± 0.4 24.1 ± 0.4
Week 12 26.4 ± 0.7 26.0 ± 0.5 28.6 ± 0.5 27.7 ± 0.6
FEMALE MICE
Week 6 16.6 ± 0.5 16.8 ± 0.2 18.5 ± 0.4 17.9 ± 0.6
Week 9 18.2 ± 0.4 17.9 ± 0.2 21.0 ± 0.6 19.8 ± 0.4
Week 12 19.7 ± 0.5 20.0 ± 0.3 24.7 ± 1.0 23.1 ± 0.6
Data are mean ± standard error of the mean (SEM) of 10–16 animals per
group. At all ages, male mice weighed significantly more than female mice and
HET mice weighed more than their wild-type littermates. For further details on
statistical analysis, see text.
F(1, 50) = 24.5 and F(1, 48) = 22.5 for male and female mice,
respectively, both P < 0.001] although the extent of the effect
appeared smaller than at 6 weeks of age at the start of the CP treat-
ment (Figure 1). There were no significant differences between
wild-type mice and HET mice (Figure 1).
Two weeks after treatment had ceased and animals were tested
for baseline locomotor activity without drug injections, male
wild-type and HET mice treated previously with CP showed a
strong trend for reduced distance traveled [F(1, 50) = 4.0; P =
0.051]. In contrast, in female mice no main effects or interactions
were found (Figure 1).
Y-MAZE
After a 2 h retention period all animals appeared to be able to
remember their previous encounter with the Y-maze indicated by
a similar preference in the percentage of number of visits to the
novel arm [F(2, 82) = 22.4; P < 0.001, no interactions] and the
most time spent in the novel arm [F(2, 82) = 20.8; P < 0.001, no
interactions] (Figure 2). The total number of arm entries differed
FIGURE 1 | Total distance traveled (cm) by male and female mice in
automated photobeam cages at the start of CP55,940 (CP) treatment
at 6 weeks of age, end of CP treatment at 9 weeks of age and 2 weeks
after treatment had ceased. Wild-type and HET mice were either treated
with vehicle solution or CP from 6 to 9 weeks of age. CP treatment
significantly reduced distance traveled in the first and second session in
both sexes and distance traveled was still slightly, but significantly reduced
in male mice 2 weeks after treatment had ceased (for statistical analysis
see text). Additional effects between groups of animals analyzed with
pairwise comparison are indicated in the figure: ∗P < 0.05 for differences
between vehicle-treated controls and CP-treated mice based on main effect
of CP in ANOVA. $P < 0.05 for difference between genotypes based on
pair-wise post-hoc ANOVAs.
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significantly between genotypes [F(1, 90) = 4.9; P = 0.030] with
HETs having a higher number of arm entries indicating higher
general locomotor activity (Table 2).
NOVEL OBJECT RECOGNITION
During the introduction phase there were no differences in the
amount of time any of the groups spent investigating the two
objects (data not shown). During the recognition phase, analy-
sis of the percentage of time spent with the novel object revealed
a main effect of genotype [F(1, 73) = 8.2; P = 0.006] but no other
main effects or interactions. This reflects that HET mice spent
less time with the novel object compared to wild-type controls
indicating poorer object recognition memory in this genotype.
Inspection of the data (Figure 3) suggests that this was particu-
larly prominent in male mice but there was no main effect of sex
of the animals nor a genotype × sex interaction.
PREPULSE INHIBITION OF ACOUSTIC STARTLE
Combined analysis of PPI in male and female mice revealed sig-
nificant main effects of sex of the animals [F(1, 88) = 5.0; P =
Table 2 | Total number of arm entries in the Y-maze after a 2-h
retention period.
WT/veh WT/CP HET/veh HET/CP
Male mice 35.5 ± 2.3 36.7 ± 4.2 35.6 ± 2.3 42.3 ± 3.4
Female mice 39.1 ± 3.3 32.9 ± 2.7 41.6 ± 3.1 40.7 ± 1.5
Data are expressed as mean ± SEM. HET mice had a higher number of arm
entries. For statistical analysis, see text.
0.028], genotype [F(1, 88) = 23.8; P < 0.001], acute CP treatment
[F(1, 88) = 22.4; P < 0.001] and an interaction of acute CP × sex
× prepulse intensity [F(3, 264) = 3.8; P = 0.010].
In male mice, ANOVA revealed a main effect of genotype
[F(1, 46) = 7.3; P = 0.010], reflecting that PPI was generally lower
in HET compared to wild-type mice (Figure 4). Acute CP treat-
ment increased PPI [F(1, 46) = 14.1; P < 0.001] and this effect
was different depending on the prepulse intensity [F(3, 138) = 4.8;
P = 0.003, Figure 5] and tended to interact with genotype and
young-adult pre-treatment [F(1, 46) = 3.7; P = 0.059]. Analysis
for each prepulse intensity separately revealed that at PP8 and
PP16 all groups showed a significant increase in PPI upon acute
CP injection [main effects F(1, 46) = 15.3 and 28.7, respectively,
both P < 0.001, no interactions]. In contrast, analysis of PP2
revealed a CP× genotype× pre-treatment interaction [F(1, 46) =
5.2; P = 0.028] and further analysis showed a marked increase in
PPI at the PP2 intensity [F(1, 10) = 8.1; P = 0.017] in HET mice
pre-treated with CP but not in any of the other groups (Figure 5).
There were no significant effects at PP4.
Inspection of the data (Figures 4, 5) revealed that HET mice
pre-treated in young-adulthood with CP had the lowest base-
line PPI of all groups which could explain their larger response
to subsequent acute CP treatment. However, further analysis in
the four groups after acute injection of saline only confirmed
the generally lower PPI in HET mice [main effect of geno-
type: F(1, 46) = 11.7; P = 0.001] independent of adolescent CP
pre-treatment (Figure 4). Interestingly, analysis of data obtained
after acute CP injection showed no genotype effect, suggesting
normalization of PPI in the HET mice by acute CP injection
(Figure 4).
FIGURE 2 | Y-maze behavior after a 2h retention period of BDNF
heterozygous (HET) and wild-type (WT) mice treated with vehicle
(veh) or CP55,940 (CP). (Top) show the percentage number of entries
into the start, novel and “other” arm of the Y-maze during the 5min
re-exposure session and the (Bottom) show the duration of time spent in
each arm. Data are presented for male (Left) and female mice (Right) and
are expressed as mean ± SEM. ∗P < 0.05 for difference between novel
arm, start arm, and “other” arm based on ANOVA. All groups showed
significant preference for the novel arm and there were no effects of
genotype or CP treatment.
Frontiers in Behavioral Neuroscience www.frontiersin.org October 2013 | Volume 7 | Article 149 | 5
Klug and van den Buuse BDNF, cannabinoids, and PPI
FIGURE 3 | Percentage of time exploring the novel object in the
recognition phase of the novel object recognition test. Data are for
male and female wild-type (WT) and BDNF heterozygous mice (HET)
treated with vehicle (veh) or CP55,940 (CP) and are expressed as mean ±
SEM. ∗P < 0.05 for difference between HET mice and wild-type controls
based on ANOVA main effect. HET mice spent less time with the novel
object compared to wild-type controls but there was no effect of
young-adult CP treatment.
Also in female mice PPI was lower in HET compared to
wild-type controls [F(1, 42) = 18.4; P < 0.001, Figure 4]. Acute
CP treatment increased PPI [F(1, 42) = 8.7; P = 0.005, Figure 4]
and, similar to male mice, this effect was greatest at higher pre-
pulse intensities [CP× prepulse interaction: F(3, 126) = 11.7; P <
0.001, Figure 5]. Further analysis for each prepulse intensity con-
firmed this observation as a significant main effect of acute CP
treatment was found in all groups at PP8 and PP16 [F(1, 42) =
14.5 and 20.4, respectively, both P < 0.001, no interactions] but
not PP4 or, in contrast to male mice, PP2 (Figure 5).
STARTLE RESPONSES
Average baseline startle amplitude was significantly lower in
female mice than in male mice [F(1, 87) = 8.9; P = 0.004] and
HET mice had higher startle compared to wild-type mice inde-
pendent of the sex of the animals [F(1, 97) = 14.4; P < 0.001;
Figure 6]. Acute CP injection significantly decreased average star-
tle [F(1, 87) = 56.7; P < 0.001], an effect which was greater in
HETmice [CP× genotype interaction: F(1, 87) = 6.9; P = 0.010]
but was independent of the sex of the animals. However, when
analysis was split up by genotype both groups were significantly
affected by acute CP injection ([F(1, 50) = 13.6; P = 0.001 and
F(1, 39) = 41.9; P < 0.001] for wild-type and HET mice, respec-
tively, Figure 6). Notably, the acute effect of CP on startle was
not affected by chronic young-adult CP treatment in any of the
groups (Figure 6).
Startle habituation occurred in all groups as indicated by
a main effect of block [F(3, 261) = 104.2; P < 0.001]. Overall,
female mice showed less startle habituation than male mice
[F(3, 261) = 4.1; P = 0.008] but there was no difference between
the genotypes in terms of startle habituation (Figure 7). Acute
CP treatment reduced startle habituation in a manner dependent
FIGURE 4 | Average percentage PPI in the four treatment groups:
WT/veh, WT/CP, HET/veh, and HET/CP in both sexes. All groups were
administered saline (Sal; open bars) and 0.4mg/kg CP55,940 (CP; black
bars) before the PPI test. HET mice had significantly lower PPI after saline
injection compared to wild-type controls. Acute CP treatment increased PPI
in male “two hit” mice and in all female groups. ∗P < 0.05 for difference
with acute saline based on genotype × acute treatment interaction and
post-hoc comparisons (males) or main ANOVA effect (females). ∗∗P < 0.05
for difference between HET mice and wild-type controls based on ANOVA
main effect.
on young-adult CP pre-treatment [F(3, 261) = 2.9; P = 0.037]. In
male mice, there were no effects of acute CP injection on star-
tle habituation (Figure 7). In contrast, in female mice, acute CP
injection reduced startle habituation [CP × block interaction:
F(3, 123) = 5.8; P = 0.001] and this effect was particularly promi-
nent in animals which had received young-adult chronic pre-
treatment with CP [F(3, 123) = 2.9; P = 0.039]. Thus, in female
mice previously treated with saline, acute CP had no effect on
startle habituation whereas in female mice previously treated with
CP in young-adulthood, acute CP reduced startle habituation
[F(3, 60) = 6.4; P = 0.001]. Notably, none of these effects were
different between wild-type and HET mice (Figure 7).
[3H]CP55,940 BINDING
Analysis of binding densities in the nucleus accumbens (Figure 8)
revealed a significant effect of chronic young-adult CP treatment
which was dependent on the genotype of the animals [F(1, 40) =
5.8; P = 0.021] and there was also a sex × genotype interaction
[F(1, 40) = 5.7; P = 0.022]. Further analysis in wild-type mice
showed that females had higher CP binding thanmales [F(1, 22) =
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FIGURE 5 | Percentage prepulse inhibition (PPI) expressed per prepulse
intensity in the four treatment groups: WT/veh, WT/CP, HET/veh, and
HET/CP in both sexes. All groups were administered saline (Sal; open
bars) or 0.4mg/kg CP55,940 (CP; black bars) PP2, PP4, PP8, and PP16
indicate prepulse intensities of 2, 4, 8, and 16 dB over the 70 dB background
with a 100ms interstimulus interval. Data are mean ± SEM. ∗P < 0.05 for
difference with acute saline treatment based on ANOVA main effect (PP8
and PP16) or CP × genotype × pre-treatment interaction and pair-wise
comparison (PP2).
5.6; P = 0.027] irrespective of prior CP exposure (Figure 8). In
contrast, in HET mice, CP binding was significantly up-regulated
[F(1, 18) = 6.5; P = 0.020] and this effect appeared to be greatest
in male mice (Figure 8) although the sex×CP term did not reach
statistical significance. Indeed, analysis of data from male mice
showed a significant CP × genotype interaction [F(1, 20) = 4.7;
P = 0.041] with no such effect in female mice, suggesting a selec-
tive up-regulation of cannabinoid binding density in the nucleus
accumbens of male BDNF HET mice, but not wild-type mice
(Figure 8). There were no sex differences, genotype differences
FIGURE 6 | Average startle amplitude in the four treatment groups:
WT/veh, WT/CP, HET/veh, and HET/CP in both sexes. All groups were
administered saline (Sal; open bars) and 0.4mg/kg CP55,940 (CP; black
bars). Data are mean ± SEM. ∗P < 0.05 for difference with saline based on
ANOVA main effect. ∗∗P < 0.05 for greater effect of acute CP injection in
HET mice based on ANOVA CP × genotype interaction. ∗∗∗P < 0.05 for
difference in startle amplitudes between WT and HET mice based on
ANOVA main effect.
or effects of young-adult CP treatment in the caudate nucleus
(Figure 8).
DISCUSSION
The main findings of this study were that chronic young-adult
treatment with a cannabinoid receptor agonist did not affect
cognition or baseline PPI in adulthood in either wild-type or
BDNF HET mice. However, acute injection of CP had differen-
tial effects on PPI depending on previous exposure to the drug as
well as genotype and sex of the animals. Thus, male BDNF HET
mice previously treated with CP showed a large increase in PPI
upon acute CP treatment in adulthood whereas the other groups
showed smaller or non-significant responses. This effect was par-
alleled by a significant increase of [3H]CP55,940 binding in the
nucleus accumbens of male BDNF HET mice previously treated
with CP.
In a previous study (Klug et al., 2012), we did not observe the
lower baseline PPI seen in BDNF heterozygousmice in the present
results. However, in that study, corticosterone was administered
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FIGURE 7 | Startle habituation expressed per startle block in the four
treatment groups: WT/veh, WT/CP, HET/veh, and HET/CP in both
sexes. All groups were acutely administered saline (Sal; open circles) and
0.4mg/kg CP55,940 (CP; black squares). Data are mean ± SEM. ∗P < 0.05
for acute CP injection to reduce startle habituation in female WT and HET
mice previously treated with CP in young-adulthood based on ANOVA
interaction. Even though acute CP injection reduced startle overall (see
Figure 6), it had no effect on startle habituation in any of the other groups.
For statistical analysis, see text.
via the drinking water whereas CP55,940 was chronically injected
in the present study. This chronic injection procedure may have
induced or unmasked a lasting PPI deficit at baseline in BDNF
HET mice. Furthermore, the PPI deficit was accompanied by an
increase in startle amplitude which may have confounded the PPI
result and was not seen in our previous study in BDNF HETmice
(Klug et al., 2012). One explanation could be that BDNF HET
mice show increased anxiety which could lead to an increase in
startle amplitude. However, only one study found an increase in
anxiety-like behavior (Chen et al., 2006) while most other studies
did not find an anxiety-like phenotype on BDNF heterozygous
FIGURE 8 | Top: typical autoradiograms of [3H]CP55,940 binding in the
mouse forebrain, showing total binding (left) and non-specific binding
(right). Specific binding densities were expressed as fmol/mg estimated
tissue equivalent (ETE) in the nucleus accumbens (Middle) and caudate
nucleus (Bottom) of male and female WT/veh, WT/CP, HET/veh, and
HET/CP. Data are mean ± SEM. ∗∗P < 0.05 for difference with BDNF HET
mice which had received chronic vehicle injections.
mice (Montkowski and Holsboer, 1997; Macqueen et al., 2001;
Chourbaji et al., 2004; Ibarguen-Vargas et al., 2009). Another
explanation for the enhanced startle amplitude could be the dif-
ference in bodyweight between the genotypes. HET mice had
significantly higher bodyweights than wild-type mice and this
could at least in part account for greater startle amplitudes.
Chronic CP treatment during young adulthood did not lead
to a deficit in baseline PPI in adulthood which is similar to what
we observed in a recent study in rats (Klug and Van Den Buuse,
2012). Acute injection of CP increased PPI and in male mice
this was predominantly in HETs previously treated in young-
adulthood with CP. In another study, acute injections of CP was
shown to cause a decrease of PPI in wild-type mice but this effect
disappeared when the mice were treated chronically (Boucher
et al., 2011). It is possible that CP can influence PPI in both direc-
tions which would be in accordance with studies in rats where
some studies found a decrease in PPI (Martin et al., 2003; Malone
and Taylor, 2006) while others reported increased PPI (Stanley-
Cary et al., 2002). This may be due to methodological differences
between the studies as it has been shown that different solvent
agents can influence the behavioral outcome (Stanley-Cary et al.,
2002). However, Boucher et al. used a similar method to ours to
dissolve their CP and showed decreased PPI in wild-type mice
after acute treatment (Boucher et al., 2011). The group of BDNF
HET male mice previously exposed to CP which responded with
an increase in PPI also had the lowest PPI score of all male groups
at baseline. After acute treatment with CP, PPI levels were indis-
tinguishable in this group from the other groups. This seems
to be comparable to cannabis self-medication which has been
Frontiers in Behavioral Neuroscience www.frontiersin.org October 2013 | Volume 7 | Article 149 | 8
Klug and van den Buuse BDNF, cannabinoids, and PPI
suggested in people with schizophrenia as a means to alleviate
some of their symptoms (Phillips and Johnson, 2001; Schofield
et al., 2006). It is possible that CB1 receptor stimulation is effective
in reversing disruptions of PPI or other schizophrenia-relevant
behaviors, independent of its effect on baseline behaviors. For
example, similar to our present results, acute treatment with
a CB1 receptor agonist reversed PPI deficits in psychosocially
stressedmice (Brzozka et al., 2011) and phencyclidine-treated rats
(Spano et al., 2010). On the other hand, in an isolation-rearing
stress model, Malone and Taylor (2006) observed a decrease
of PPI after acute treatment with THC, which had no effect
in normally-housed control (Malone and Taylor, 2006). Future
studies could focus on the effects of cannabinoid receptor stimu-
lation in other models of genetic or environmentally-induced PPI
disruptions. For example, recently it was shown that BDNF treat-
ment produced long-lasting reversal of PPI deficits in DBA mice
(Naumenko et al., 2013) and it would be of interest to study the
acute and chronic effects of cannabinoid receptor stimulation in
this strain.
Some caution is needed when interpreting the PPI results
as acute treatment with CP reduced startle amplitudes which
may have confounded PPI. The reduction in startle response is
most likely related to adverse effects of the cannabinoid agonist
that include hypoactivity and catalepsy (Chaperon and Thiebot,
1999). Other studies have also failed to detect cannabinoid-
induced effects in PPI that were not accompanied by impairment
in startle reflex (Nagai et al., 2006; Boucher et al., 2011). For
example, Martin et al. only found a PPI deficit when rats were
treated with the highest dose of CP which also decreased startle
amplitudes. When the animals were treated with a lower dose,
no effects on startle reactivity were observed but the previously
observed PPI deficit had vanished as well, showing that CP treat-
ment does not impair PPI without affecting startle (Martin et al.,
2003). This raises the possibility that the effects of CP on PPI are
not a real impairment in sensorimotor gating (Swerdlow et al.,
2000). Further studies should be considered to see whether a
smaller dose of CP would lead to an enhancement in PPI with-
out affecting startle amplitudes. It noteworthy, though that CP
only increased PPI in some groups while it reduced startle in all
groups, which would suggest that the presently observed selective
PPI changes are independent of the effect of CP on startle.
The selective increase in the effect of acute CP in male BDNF
HET mice previously treated with the drug, was paralleled by a
selective increase in CP binding density in the nucleus accumbens
in these mice. The nucleus accumbens plays an important role in
PPI regulation (Shilling et al., 2008; Roncada et al., 2009). CB1
receptors are present on fast-spiking interneurons in this nucleus
which form inhibitory GABAergic synapses with medium-spiny
interneurons and modulate its activity (Winters et al., 2012).
These neurons can also modulate behavioral effects of dopamin-
ergic psychotropic drugs (Corbille et al., 2007) and the selective
up-regulation of CP binding density in the present study may
explain the enhanced effect of acute treatment with the drug on
PPI. Similar to the present results, previous studies have found
that chronic cannabinoid receptor agonist treatment could influ-
ence CB1 receptor levels and function even long after treatment
had finished (Zamberletti et al., 2012). However, it is important
to note that the single-point agonist binding method used here
does not distinguish between possible changes in Kd or Bmax
of the receptor. Therefore, future, more elaborate binding stud-
ies are needed to extend the present results and ascertain the
molecular basis of the changes in [3H]-CP55,940 binding density.
These further studies could also include other CB1 compounds as
displacing agents.
Another possible mechanism involved in the present results
could be the effect of acute and chronic CP treatment on BDNF
levels. Previous animal studies have shown that THC increases
BDNF gene expression acutely (Derkinderen et al., 2003) and
after chronic administration (Butovsky et al., 2005). In human
studies, THC increased serum BDNF levels in healthy controls,
but not in chronic cannabis users (D’souza et al., 2009). It would
be of interest to assess if young-adult CP treatment, as used
in the present study, induced long-term reversal of the reduced
BDNF levels seen in BDNF HET mice (Hill and Van Den Buuse,
2011). This might also explain the sex differences observed in the
present study, as young-adult developmental changes in BDNF
levels showed marked male-female differences in normal mice
(Hill et al., 2012) and sex-specific alterations in BDNF signaling
were found in BDNF HET mice (Hill and Van Den Buuse, 2011).
In addition to its effect on PPI, chronic CP treatment also
affected locomotor activity as was expected from previous studies
(McGregor et al., 1996; Boucher et al., 2011; Llorente-Berzal et al.,
2011). Interestingly, male mice treated with CP during young-
adulthood showed reduced locomotor activity even 2 weeks after
treatment had ceased. This is similar to what we observed in
rats (Klug and Van Den Buuse, 2012) and it seems that male
animals are more prone toward the long-term effects that CP
can exert on locomotor activity. There were other, more subtle
and sex-dependent differences in locomotor activity between the
genotypes at 6 and 9 weeks. However, none of these effects were
seen in adulthood at 11 weeks of age similar to what has been
observed in previous studies (Chourbaji et al., 2004; Saylor and
McGinty, 2008; Klug and Van Den Buuse, 2012).
No effects of either genotype, cannabinoid treatment or the
combination of the two were observed in the Y-maze tasks. All
animals spent more time in the novel arm which is an indicator
for intact short-term spatial memory (Dellu et al., 2000). In a pre-
vious study, we observed marked deficits in Y-maze performance
in male BDNF HET mice treated chronically with corticosterone
in young adulthood (Klug et al., 2012). These differential results
show that various young-adult “second hits” can have markedly
different outcome in adulthood, in this case corticosterone expo-
sure compared to cannabinoid treatment. Novel object recogni-
tion was impaired in BDNF HET mice which has been reported
before (Seoane et al., 2011). However, similar to Y-maze perfor-
mance, there was no effect of chronic CP treatment, strengthening
the selectivity of its action on PPI. Thus, although previous stud-
ies have shown involvement of both the endocannabinoid system
and BDNF in memory formation and consolidation (Papaleo
et al., 2011; Panlilio et al., 2012; De Bitencourt et al., 2013; Wright
et al., 2013), in our protocol including chronic CP treatment fol-
lowed by a 2-week washout, there were no such effects. Future
studies could include the acute effects of cannabinoid recep-
tor stimulation on memory function in BDNF HET mice and
controls after chronic pre-treatment with CP, similar to the PPI
studies presented here.
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